BIA Separations Announce Asia Distribution Deals
BIA Separations has announced the company has signed agreements with Bioscience companies, GeneX India Biosciences, Chennai, India and IT Technologies (IT Tech), Singapore. Both Companies will act as sole distributors of BIA Separations’ products and services across their respective regions of India, and Singapore and Malaysia.
“We are delighted to have GeneX India and IT Tech on board and look forward to jointly providing researchers and process developers across Asia with our state-of-the-art bioprocessing technologies and services,” said Ingo S. Nagler, Business Development Officer,
BIA Separations
BIA Separations provides research and method development services for the purification of large and complex biomolecules including those with therapeutic applications. Through the agreements, both distributors will provide academic researchers, CMOs, and biopharmaceutical companies access to BIA Separations’ proprietary analytical and preparative purification technologies for cell and gene therapies, including viral vectors, nucleic acids, phages, and exosomes.
“We are very proud to be working with the team [BIA Separations] to ensure its leading purification technologies and expertise are available to research and bioproduction customers throughout India,” said Felix Paul, Managing Director GeneX India Biosciences.
“Cell and gene therapy is still at an early stage here [Malaysia], and therefore this is an exciting time to be signing a partnership with BIA Separations, enabling us to offer the Company’s products and services across research in this high-potential field,” said Danapalan Arumugam, Managing Director at IT Tech.
For more information, please visit: www.biaseparations.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
